Cas:20812-13-9 5-methylsulfonyl-1,3-thiazol-2-amine manufacturer & supplier

We serve Chemical Name:5-methylsulfonyl-1,3-thiazol-2-amine CAS:20812-13-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-methylsulfonyl-1,3-thiazol-2-amine

Chemical Name:5-methylsulfonyl-1,3-thiazol-2-amine
CAS.NO:20812-13-9
Synonyms:2-amino-5-methylsulfonylthiazole;5-Methansulfonyl-thiazol-2-ylamin;2-amino-5-methylsulphonyl-thiazole;5-methanesulfonyl-thiazol-2-ylamine
Molecular Formula:C4H6N2O2S2
Molecular Weight:178.23300
HS Code:2934100090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:446.7ºC at 760 mmHg
Density:1.533g/cm3
Index of Refraction:1.6
PSA:109.67000
Exact Mass:177.98700
LogP:1.79080

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-amino-5-methylsulfonylthiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-methanesulfonyl-thiazol-2-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Methansulfonyl-thiazol-2-ylamin Use and application,5-methanesulfonyl-thiazol-2-ylamine technical grade,usp/ep/jp grade.


Related News: First of all, as an API manufacturer we think of how to make a chemical compound which becomes an API in the laboratory. 5-methylsulfonyl-1,3-thiazol-2-amine manufacturer The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. 5-methylsulfonyl-1,3-thiazol-2-amine supplier The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s (EBS.N) plant for manufacturing the J&J vaccine. 5-methylsulfonyl-1,3-thiazol-2-amine vendor First of all, as an API manufacturer we think of how to make a chemical compound which becomes an API in the laboratory. 5-methylsulfonyl-1,3-thiazol-2-amine factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.